U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H25N5O10
Molecular Weight 495.44
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NIKKOMYCIN Z

SMILES

C[C@@H]([C@H](N)C(=O)N[C@@H]([C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C=CC(=O)NC2=O)C(O)=O)[C@H](O)C3=CC=C(O)C=N3

InChI

InChIKey=WWJFFVUVFNBJTN-VHDFTHOZSA-N
InChI=1S/C20H25N5O10/c1-7(13(28)9-3-2-8(26)6-22-9)11(21)17(31)24-12(19(32)33)16-14(29)15(30)18(35-16)25-5-4-10(27)23-20(25)34/h2-7,11-16,18,26,28-30H,21H2,1H3,(H,24,31)(H,32,33)(H,23,27,34)/t7-,11-,12-,13-,14-,15+,16+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H25N5O10
Molecular Weight 495.44
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Nikkomycin Z is an antifungal drug that inhibits chitin synthase. It has been reported that it inhibits chitin synthases (Chs) 1 and 3, but not 2, of Saccharomyces cerevisiae. Later it was found that nikkomycin Z inhibited all three Chs isozymes of Candida albicans (CaChs). The IC(50) value for CaChs1 is 15 uM, for CaChs2 0.8 uM, and for CaChs3 13 uM. Nikkomycin Z is under development as an orphan product for treatment of coccidioidomycosis. Nikkomycin Z has been used in trials studying the treatment and basic science of Coccidioidomycosis. In February 2006, nikkomycin z was designated as an orphan drug for the treatment of Coccidioidomycosis.

Originator

Curator's Comment: Nikkomycin Z was first discovered by scientists at German pharmaceutical company, Bayer AG.

Approval Year

PubMed

PubMed

TitleDatePubMed
Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens.
2000-09
Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.
2000-02
In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole.
1999-06
Efficacy of nikkomycin Z in the treatment of murine histoplasmosis.
1998-09
Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.
1992-06
Synthesis and biological evaluation of dipeptidyl and tripeptidyl polyoxin and nikkomycin analogues as anticandidal prodrugs.
1991-01
Synergistic action of nikkomycins X and Z with papulacandin B on whole cells and regenerating protoplasts of Candida albicans.
1986-03
Patents

Sample Use Guides

Safety and pharmacokinetics of nikkomycin Z were evaluated in healthy male subjects following single, rising oral doses ranging from 250 mg to 2,000 mg. Pharmacokinetics appeared linear over the range of 250 to 500 mg; however, relative bioavailability was about 62 to 70% for the 1,000-mg dose and 42 to 47% for doses between 1,500 and 2,000 mg.
Route of Administration: Oral
Nikkomycin Z inhibited all three Chs isozymes of Candida albicans (CaChs). The IC(50) value for CaChs1 is 15 uM, for CaChs2 0.8 uM, and for CaChs3 13 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:29:34 GMT 2025
Edited
by admin
on Mon Mar 31 18:29:34 GMT 2025
Record UNII
9Z22C3QQCJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NSC-601906
Preferred Name English
NIKKOMYCIN Z
Common Name English
NEOPOLYOXIN C
Common Name English
.BETA.-D-ALLOFURANURONIC ACID, 5-(((2S,3S,4S)-2-AMINO-4-HYDROXY-4-(5-HYDROXY-2-PYRIDINYL)-3-METHYL-1-OXOBUTYL)AMINO)-1,5-DIDEOXY-1-(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)-
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 217505
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
Code System Code Type Description
NSC
601906
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
PUBCHEM
456557
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
EPA CompTox
DTXSID5058436
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
DRUG BANK
DB12939
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
CHEBI
623918
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
CAS
59456-70-1
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
FDA UNII
9Z22C3QQCJ
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
MESH
C011952
Created by admin on Mon Mar 31 18:29:34 GMT 2025 , Edited by admin on Mon Mar 31 18:29:34 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT